Business Services
Medical
Biotechnology
Altimmune
$2.519876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.08 (3.29%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Altimmune and other stocks, options, ETFs, and crypto commission-free!
About
Altimmune, Inc. Common Stock, also called Altimmune, is a clinical stage immunotherapeutic biotechnology company, which is focused on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. Read More Its portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Employees
27
Headquarters
Gaithersburg, Maryland
Founded
1997
Market Cap
22.79M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
790.88K
High Today
$2.52
Low Today
$2.39
Open Price
$2.47
Volume
82.61K
52 Week High
$36.25
52 Week Low
$1.70
Collections
Business Services
Medical
Biotechnology
Cancer Prevention
Health
US
North America
News
Seeking AlphaMay 15
Altimmune, Inc. CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT) Q1 2019 Earnings Conference Call May 15, 2019 8:30 AM ET Company Participants Vipin Garg - Chief Executive Officer Will Brown - Acting Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Jerry Isaacson - ROTH Capital Operator Greetings, and welcome to the Altimmune First Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation...
Price Paid on Robinhood
36% Lower
Right Now
52 Week Low
$1.70
Average Price Paid
$3.92
52 Week High
$36.25
Earnings
-$3.60
-$2.43
-$1.25
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
-$0.27 per share